KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

PHASE3CompletedINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

March 13, 2018

Primary Completion Date

June 20, 2019

Study Completion Date

July 9, 2019

Conditions
ADHD
Interventions
DRUG

KP415 oral capsule

Once-daily oral dose

Trial Locations (19)

32256

Clinical Neuroscience Solutions, Inc., Jacksonville

32751

Meridien Research, Maitland

32801

Clinical Neuroscience Solutions, Inc., Orlando

33319

Innovative Clinical Research, Inc., Lauderhill

34201

Meridien Research, Bradenton

38119

Clinical Neuroscience Solutions, Inc., Memphis

44718

Neuro-Behavioral Clinical Research, Canton

45417

Midwest Clinical Research Center, LLC, Dayton

60048

Capstone Clinical Research, Libertyville

66211

Psychiatric Associates, Overland Park

72211

Woodland International Research, Little Rock

77007

Bayou City Research, Ltd., Houston

77098

Houston Clinical Trials, Houston

78731

FutureSearch Trials, Austin

80910

MCB Clinical Research Centers, Colorado Springs

89128

Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas

97214

Oregon Center for Clinical Investigations, Inc., Portland

97301

Oregon Center for Clinical Investigations, Inc., Salem

08009

Hassman Research Institute, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Zevra Therapeutics

INDUSTRY